Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

Home Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

/ Publications

Share the Post

About the Author

Related Posts

Study-end analysis from AMPECT, an open-label, phase 2 registration trial of patients with advanced malignant PEComatreated with nab-sirolimus, showing durability of response and long-term safety
Read More
Stephen Rodin, JD
Read More
Scott Giacobello, CPA
Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021
Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO™) in Greater China
Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication
Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer
Read More
Neil Desai, PhD

Comments

Comments are closed.